

or unsubstituted, heterocyclic or carbocyclic, aromatic or non-aromatic, ring system,  
optionally substituted at the boron atom.

### REMARKS

The claims have been made subject to a four-way restriction requirement. The original claims have been cancelled and a new set of claims are presented for prosecution. Claim 1 corresponds to original claim 11 which was categorized as Claim Group II. Applicant provisionally elects to prosecute the Group II claims.

It is respectfully submitted that claim 24 and claims 25-44 which depend therefrom, are all appropriately grouped as category II claims. Although some claims, such as claim 39 which recites a light emitting device, do not claim a complex per se, they are properly maintained in a single application pursuant to M.P.E.P. §806.05(c). Clearly the inventive concept with respect to claim 39 resides in the complex as defined by claim 1 and as such the dependent claims are properly includable in the same application.

With respect to claims 45 and 46, it is respectfully submitted they correspond with the Group I claimed subject matter. In this regard, the restriction requirement is respectfully traversed. Although the complex recited in conjunction with claim 45 is somewhat broader than independent claim 24 it is respectfully submitted that claim is not anticipated by the reference cited by the Examiner, namely U.S. Patent 5,707,745 (Forrest et al.). Forrest et al. discloses, at column 17 (claim 14), a light emitting device containing a complex having the formula  $MDL^4_2$ . In this formula, M is a trivalent metal and may be a lanthanide metal, D is a bidentate ligand, such as picolylketone, quinaldylketone or phenoxypyridine (see Fig. 8A) and the ligand  $L^4$  may be the bispyrazolyl borane shown (this is shown in Fig. 8E). Thus, the formula depicted in claim 14 of this U.S. Patent is for a complex which contains three

**Applicant:** Victor Christou  
**Application No.:** 09/445,050


ligands, two of which contain pyrazolyl groups and one of which contains groups other than pyrazolyl groups. The device claimed in claim 45 comprises a complex in which all of the ligands comprise one or more pyrazolyl groups.

Reconsideration and withdrawal of the restriction requirement and allowance are respectfully requested.

Respectfully submitted,

Victor Christou

By

  
C. Frederick Koenig III, Esquire  
Registration No. 29,662  
(215) 568-6400

Volpe and Koenig, P.C.  
Suite 400, One Penn Center  
1617 John F. Kennedy Boulevard  
Philadelphia, PA 19103

CFK/fap